1. Home
  2. ACP vs KALV Comparison

ACP vs KALV Comparison

Compare ACP & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Income Credit Strategies Fund

ACP

abrdn Income Credit Strategies Fund

HOLD

Current Price

$5.49

Market Cap

675.0M

Sector

Finance

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$16.33

Market Cap

551.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACP
KALV
Founded
2010
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
675.0M
551.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACP
KALV
Price
$5.49
$16.33
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$27.83
AVG Volume (30 Days)
337.9K
956.5K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
17.79%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,426,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$204.16
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.55
$7.30
52 Week High
$7.17
$17.30

Technical Indicators

Market Signals
Indicator
ACP
KALV
Relative Strength Index (RSI) 55.83 60.08
Support Level $5.35 $15.12
Resistance Level $5.48 $16.45
Average True Range (ATR) 0.05 0.88
MACD 0.01 -0.06
Stochastic Oscillator 79.41 82.78

Price Performance

Historical Comparison
ACP
KALV

About ACP abrdn Income Credit Strategies Fund

abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: